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This study  investigated  the  effects  of  pre-  and  peripubertal  exposure  (PND  15–45) to
triphenyltin  hydroxide  (TPT:  0, 1.875,  3.75,  7.5  and  15  mg/kg  bw/d  po)  on mouse  sexual
maturation  and fertility.  Half  of  the  mice  were  euthanized  on  PND  46  and  the  remaining
mice  were  submitted  to fertility  tests  on PND  65–75. TPT  caused  a  transient  decrease  of
weight  gain  at  3.75 mg/kg  bw/d,  and  deaths  and  body  weight  deﬁcits  at higher  doses.  Delays
of testes  descent  (TD),  vaginal  opening  (VO)  and  ﬁrst estrus  (FE)  occurred  at doses  ≥3.75
(TD) and ≥7.5  mg/kg  bw/d  (VO,  FE),  respectively.  Body  weight  on  the  days  of  TD, VO  and
FE  did  not  differ  among  groups.  TPT  at doses  ≥3.75  mg/kg  decreased  sperm  and  spermatid
counts  at the  end  of  treatment  (PND  46) but no alteration  was  noted  later  on  PND  75.
Testicular  histopathology  (PND  46) showed  a dose-dependent  reduction  of  seminiferous
tubules  diameter,  a  greater  degree  of vacuolation  in  Sertoli  cells  and germ  cell  degener-ostnatal exposure
ertility
ation  and  necrosis  in TPT-treated  mice.  TPT  did  not  affect  the  outcome  of fertility  tests.
Study-derived  NOAEL  was  1.875  mg  TPT/kg  bw/d  for males  and 3.75  mg  TPT/kg bw/d  for
females.  The  detrimental  effects  of  TPT  on spermatogenesis  were  reversed  after  treatment
discontinuation.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. IntroductionTriphenyl (TPT) and tributyl (TBT) tins are powerful
iocides (algicides, acaricides, insecticides, molluscicides,
iticides, fungicides, slimicides, bactericides) that have a
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diversity of applications such as agricultural pesticides, dis-
infectants, preservatives for wood and antifouling agents
in paints for ship hulls and ﬁsh farm nets and cages. The
marked toxicity and putative endocrine disrupting prop-
erties of organotin compounds have raised concerns about
the impact of their widespread use on the environment and
human health.
Marine contamination by tri-substituted organotins has
been associated with increased occurrence of imposex, or
the superimposition of male type genital organs (penis and
vas deferens), in female bivalve and gastropod mollusks
[25]. Since TBT and TPT act as competitive inhibitors of a
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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cytochrome P450-aromatase that converts androgen into
estrogen, it has been hypothesized that imposex might
result from elevated concentrations of unconverted andro-
gens in organotin-exposed mollusks [9]. Some authors,
however, pointed out that while organotin compounds
are potent inducers of imposex, their effective concen-
trations as aromatase inhibitors are high. Along this line,
hypotheses about modes of action other than inhibition of
aromatase have been proposed for imposex [9].
A variety of potential deleterious effects of tri-
organotins on mammals have been described including
a marked toxicity to mammalian development [20] and
reproduction. Nonetheless, the critical molecular tar-
gets for organotin induced reproductive toxicity remain
unclear. Within this context, it has been debated whether
aromatase inhibition plays a role in mediating devel-
opmental toxic effects of tri-organotin compounds on
mammals. Nakanishi [15], for instance, reported that
in human choriocarcinoma cells, organotins instead of
inhibiting estradiol biosynthesis substantially enhanced it
along with an increase of both aromatase activity and 17-
hydroxysteroid dehydrogenase type I activity, an enzyme
that converts estrone (a weak estrogen) into the bio-
logically active estrogen 17-estradiol at the same low
concentrations.
Several studies including those by Kanayama et al. [10]
Hiromori et al. [8], and Le Maire et al. [12] demonstrated
that TBT and TPT are nanomolar agonists for retinoid
X receptor alpha (RXR-)  and peroxisome proliferator-
activated receptor (PPAR) gamma. Along this line, it has
been suggested that some toxic effects (and potential anti-
cancer effects) of organotin compounds are mediated via
actions on the RXR and PPAR-  nuclear receptors [15].
Although a number of studies have found detrimental
effects of tri-organotins (TBT and TPT) on rodent repro-
ductive organs and function, mostly in rats, reports in
the literature are far being consistent among compounds,
doses and routes of exposure, species and toxic responses.
A study by Podratz et al. [11], for instance, described
that TBT given orally to adult rats, at a dose as low as
100 ng/kg bw/d for two weeks, disrupted cycling regular-
ity, markedly reduced ovary weights and 17-estradiol
concentrations in the serum, increased progesterone con-
centrations and produced histological changes in the ovary.
Similar histological ﬁndings (increased number of atretic
tertiary and preovulatory follicles) were noted by Water-
mann et al. [26] in rats receiving TPTCl at an oral dose as
high as 6 mg/kg bw/d from PND 23 until 53, while only
minor changes were found at a lower dose (2 mg/kg bw/d).
Moreover, Grote et al. [5] reported that in female rats TPT
(6 mg/kg bw/d po)  administered on PND 23–53 retarded
the puberty onset (day of vaginal opening) and increased
17-estradiol blood serum concentrations. A previous
study by the same authors [6] had found that oral treat-
ment of male rats with TBT (15 mg/kg bw/d) or TPT (6 and
12 mg/kg bw/d) during the pre- and peripubertal periods
(PND 23–53) also delayed puberty onset (preputial separa-
tion), and decreased testosterone and luteinizing hormone
(LH) serum concentrations.
The reproductive toxicity of tri-organotin compounds
was less studied in mice than in rats. Nonetheless, Si et al.ports 2 (2015) 405–414
[24] described that TBT (1, 10, 100 g/kg bw/d) given orally
to female mice during gestation and lactation retarded
testes descent and acquisition of cliff-avoidance reﬂex
in the exposed offspring (100 g/kg bw/d). A subsequent
study by the authors found that a similar treatment with
TBT (gestation + lactation) advanced the day of vaginal
opening and the day of the ﬁrst estrus and that exposed
female offspring (10 and 100 g/kg bw/d) also exhibited
altered cycling regularity in adulthood [22]. Data on the
toxicity of orally administered TPT (fentin) to mice during
postnatal development have been provided as well. Del-
gado et al. [4] treated pregnant mice (GD7–17) with TPT
(7.5, 15 and 30 mg  TPT/kg bw/d po)  and noticed that the two
highest doses produced a marked perinatal mortality. Post-
natal growth, days of vaginal opening and testes descent,
and other landmarks of somatic development, however,
remained unaffected in the offspring exposed in utero to
TPT. In a further study, the authors treated female mice
with TPT (1.875, 3.75, or 7.5 mg/kg bw/d po)  during preg-
nancy and lactation (GD6–PND 21) and evaluated offspring
somatic development and fertility [21]. Results showed no
discernible effect of TPT at any tested dose on offspring
development and fertility.
This study was undertaken to investigate whether expo-
sure to TPT beginning before puberty and extending over
pubertal onset period would adversely affect sexual mat-
uration and fertility in Swiss mice. Since half of the
treated mice were evaluated at the end of treatment and
the remaining animals one month later, data were also
obtained on the reversibility of TPT induced detrimental
effects.
2. Materials and methods
2.1. Animals
Female Swiss Webster mice, from the FIOCRUZ Cen-
tral Animal House (CECAL) breeding stock, were used.
Mice were housed individually in standard plastic cages
with stainless-steel covers and autoclaved wood shav-
ings as bedding and kept under controlled temperature
(23 ± 2 ◦C), relative humidity (approximately 70%) and
day/night cycle (lights on from 8:00 a.m. to 8:00 p.m.). A
pelleted diet (Nuvital®, for laboratory rats and mice, Nuvi-
lab Ltd., Curitiba, PR, Brazil) and ﬁltered tap water were
provided ad libitum. All procedures were performed in
accordance with Brazilian animal protection and welfare
laws. The study protocol was approved by the Ethics Com-
mittee on the Use of Animals of Oswaldo Cruz Foundation
(CEUA-FIOCRUZ, License Nr 0077-01).
2.2. Mating, pregnancy, parturition and culling
Two  females were placed into the cage of one male for
2 h at the end of the dark period (6:00–8:00 a.m.) and cop-
ulation was  conﬁrmed by the presence of a vaginal plug.
The day on which mating was  conﬁrmed was designated as
pregnancy day ‘0’. From pregnancy day 18 onwards cages
were inspected twice a day (8:00 a.m. and 5:00 pm) for
deliveries. The ﬁrst 24 h after birth was considered as post-
natal day (PND) 1. On PND 5, litter size was adjusted by
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ulling to 10 pups (ﬁve females and ﬁve males, whenever
ossible). Natural litters with 10 or fewer pups were not
tandardized.
.3. Treatment, weaning and euthanasia
Triphenyltin hydroxide (TPT, purity ≥96.0%) was from
ldrich, Inc. On PND 15, all pups were weighed and allo-
ated at random (within their litters) to one of ﬁve treat-
ent groups (0, 1.875, 3.75, 7.5 and 15 mg  TPT/kg bw/d).
ale and female mice (N = approximately 40 per gender
nd treatment group) from 20 litters were daily treated
rom PND 15 through to 45. After weaning on PND 21, dams
ere euthanized and up to 5 pups of a same gender and lit-
er were housed in one cage. TPT or its vehicle alone (phar-
aceutical grade corn oil, Sigma Chemical Co.) was  admin-
stered by gavage at a ﬁxed volume of 10 mL/kg bw/d. A
ontrol group received the vehicle only. Males and females
rom 10 litters were killed on the day following that of last
ose of TPT or its vehicle (PND 45). Pups from the remaining
itters received no further treatment until euthanasia on
ND 80–90. Fertility tests took place on PND 65–70.
.4. General toxicity
During the period of treatment (PND 15–45) body
eights were determined on PNDs 15, 21, 25, 30, 35 and
5 while cages were inspected for deaths and clinical signs
f toxicity on a daily basis. Cage-side observations of clin-
cal signs of toxicity included, but were not limited to:
ehavioral abnormalities, CNS depression symptoms, slow
r irregular breathing, appearance of diarrhea, bleeding,
hanges in skin and fur, eyes and mucous membranes,
umoral masses, edema and other abnormalities.
.5. Vagina opening and testis descent
Occurrence of testes descent (by scrotum palpation) or
aginal opening (visual inspection) was evaluated every
orning (8:00–10:00 am)  from PND 15 onwards.
.6. Estrous cycle
From the day of VO onwards, for 20 consecutive
ays, vaginal smears were prepared every morning
8:00–9:00 h) to determine the day on which the ﬁrst estrus
ook place and characterize the estrous cycle. Cytological
ndings for staging the estrous cycle were as follows: pro-
strus, predominance of round pro-nucleated epithelial
ells; estrous, presence of corniﬁed epithelial cells; meta-
strous, presence of both corniﬁed epithelial cells and
eukocytes and mucus, diestrus, predominance of leuko-
ytes.
.7. Euthanasia
On the day following the last dose of TPT or its vehi-
le, pups from 10 litters selected at random were killed by
ervical dislocation. A blood sample was collected by car-
iac puncture. Liver, spleen, thymus, uterus, ovaries, testis,
pididymis and seminal vesicle with coagulating glandsports 2 (2015) 405–414 407
(without ﬂuid) were removed and weighed. Pups of the
remaining 10 litters received no further treatment.
2.8. Measurement of the number of spermatids in the
testis and epididymal sperm count
Following removal of the tunica albuginea, the right
testis from each male mouse was  minced and homoge-
nized in 1 mL  of 0.9% NaCl containing 0.5% Triton X-100 for
manual homogenization. After dilution in 0.9% NaCl, the
number of homogenization-resistant spermatids of each
testis was counted with a Neubauer chamber. Similarly, the
cauda of epididymis was cut into small pieces, minced and
homogenized, and the sperm (spermatozoa) were counted
as described above [2].
2.9. Sperm morphology
To assess the percentage of morphologically abnormal
sperm (detected in the head or tail) the deferens ducts
were rinsed with 0.3 mL  0.9% NaCl and a sperm suspen-
sion was  obtained. The smear on the slide (lamina) was
prepared with an aliquot of sperm suspension carefully
stained with Congo red and Gencian violet. Two  hundred
sperm per animal were examined at 1000× magniﬁcation
and morphologically normal and abnormal sperm were
scored according to the presence or absence of defects in
the head (e.g., double-headed, amorphous head, reduced
hook, banana head, no hook head, detached head, dwarf
head, giant head, pin head) or tail (crooked ﬂagellum, bro-
ken ﬂagellum, coiled ﬂagellum, tip coiled ﬂagellum, bent
ﬂagellum tip) of the sperm [18].
2.10. Histopathology and morphometry
The left testis from each male mouse was  ﬁxed with
Bouin’s solution that was  further replaced with Mil-
lonig’s phosphate buffered formalin as modiﬁed by Carson.
After ﬁxation, testes were embedded in parafﬁn, cut
and mounted on slides and subsequently stained with
hematoxylin/eosin. One hundred seminiferous tubules in
randomly selected cross sections of the testis from each
mouse were identiﬁed regarding the stages of spermato-
genesis. Twenty essentially round seminiferous tubules per
testis were examined to assess the mean tubule diameter.
The height of the germinal epithelium was measured in
stages VII/VIII seminiferous tubules.
2.11. Testosterone level
Plasma testosterone concentrations were determined
(samples in duplicate) using a commercially available com-
petitive immunoassay kit (Free Testosterone ELISA, ARP,
IncTM).
2.12. Fertility testFertility tests were carried out with half of mice from
each treatment group when they were approximately 65
day old. One male and 3 females from the same treatment
group and different litters (to avoid brother–sister mating),
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Table 1
Survival of mice treated orally with TPT (0, 1.875, 3.75, 7.5, 15 mg/kg bw/day) on postnatal days (PND) 15–45.
Pups alive TPT (mg/kg bw/day po)
0 1.875 3.75 7.5 15
Females
PND 15, N (%) 23 (100) 22 (100) 21 (100) 27 (100) 21 (100)
PND  45, N (%) 23 (100) 22 (100) 21 (100) 26 (96.3)a 4 (19)a,b
Males
PND 15, N (%) 26 (100) 26 (100) 24 (100) 27 (100) 26 (100)
a a,bPND  45, N (%) 26 (100) 26 (100)
a All deaths occurred between PND 21 (weaning) and PND 25.
b Differ (chi-square test, p < 0.05) from other group survival rates.
chosen at random, were housed in the same cage for 15
d. Females were examined every day in the morning for
the presence of a vaginal plug. On the day a vaginal plug
was found (GD 0), females were transferred to individual
cages. Females that had not been impregnated by males
during the ﬁrst cohabitation period were placed again into
a male cage for a second mating test. The second mating
test was similar to the ﬁrst, except that untreated males
of proven fertility were used. Males that did not impreg-
nate at least 2 females during the ﬁrst mating test had a
second 15-d cohabitation period with 3 untreated females.
On day 16 of pregnancy females were killed by CO2 inhala-
tion. The gravid uteri were weighed with their contents.
The number of dead and living fetuses and resorptions were
recorded. The number of implantation sites was deter-
mined by the Salewski’s method [19]. Liver, spleen, thymus,
gravid uterus and ovaries were removed and weighed.
Male mice that took part in the fertility test were
killed by cervical dislocation on PND 75. Liver, spleen,
thymus, testis, epididymis and seminal vesicle with coag-
ulating glands (without ﬂuid) were removed and weighed.
Collection of epididymal sperm and sperm counting was
performed as described in a previous section.
2.13. Statistical analysis
Data were analyzed by one-way analysis of variance
(ANOVA) followed by Bonferroni’s post hoc test, or by the
Kruskal–Wallis test followed by the Mann–Whitney U test,
whenever the data did not ﬁt a normal distribution. Propor-
tions were evaluated by the chi-square test or by the Fisher
exact test. Statistical evaluation was performed using a
SPSS® program and differences were considered as statis-
tically signiﬁcant whenever p < 0.05.
3. Results
3.1. Effects of TPT on pup survival and body weight gain
No clinical sign of toxicity was noted at the two  low-
est doses (1.875 or 3.75 mg/kg bw/d) of TPT. A number
of deaths, however, occurred among mice treated with
the second highest (7.5 mg/kg bw/d: 7.4% of males and
3.7% of females) and the highest (15 mg/kg bw/d: 80.8%
of males and 80.9% of females) doses of TPT. All deaths of
pups treated with TPT took place during the second week24 (100) 25 (92.6) 5 (19.2)
of treatment within a few days of weaning (PND 21–25)
(Table 1).
The body weight changes of mouse pups treated with
TPT are shown in Fig. 1. The treatment caused a dose-
dependent reduction of body weight gain in males (Fig. 1A)
at TPT doses ≥3.75 mg/kg bw/d while weight gain of
females (Fig. 1B) was decreased only at the two high-
est doses (7.5 and 15 mg/kg bw/d). It is of note that the
weight gain deﬁcit during treatment with TPT was  tran-
sient. Except for the highest dose group (15 mg/kg bw/d)
no differences in body weights between control and TPT
treated mice were noted at the end of treatment (PND45).
Except for body weight gain deﬁcit no other clinical signs
of toxicity were noted.
3.2. Effect of treatment with TPT on the onset of puberty
As shown in Table 2, the day on which landmarks of
puberty onset appear in female mice was not affected by
treatment with the lowest doses of TPT. At the two  high-
est doses (7.5 and 15 mg/kg bw/d), however, TPT delayed
the day of vaginal opening and the day of the ﬁrst estrus.
The time (days) between vaginal opening and the ﬁrst
estrus remained unaltered at all doses of TPT (Table 2).
The day of testes descent was  delayed in male pups treated
with doses of TPT ≥3.75 mg/kg bw/d. At ﬁrst sight, these
ﬁndings seem to indicate that TPT at the highest doses
tested delayed puberty onset in both male and female mice.
Nonetheless, TPT-treated pups did not differ from controls
regarding pup body weight on the days of vaginal opening,
ﬁrst estrus and testes descent (Table 2). Taken together,
these results suggest that delays of puberty onset reﬂect
a general retardation of growth and somatic maturation
rather than speciﬁc effects on male and female endocrine-
sensitive endpoints.
3.3. Effects of TPT on male reproductive organs,
testosterone concentrations, and sperm parameters at the
end of treatment period
On the day following the last dose of TPT (PND 46)
mice that had been treated with doses of TPT ≥ 3.75 mg/kg
bw/d exhibited dose-dependent reductions of the num-
ber of spermatids (testes) and spermatozoa (epididymis)
compared to controls (Table 3). A small and statistically
non-signiﬁcant increase in the proportion of sperm with
an abnormal morphology was also noted at the two  highest
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Fig. 1. Body weight gain (g) of male (A) and female (B) mice treated orally (gavage) with triphenyltin hydroxide (0, 1.875, 3.75, 7.5 or 15 mg/kg bw/d)
suspended in corn oil from postnatal day 15 through to 45. The height of the histogram bar corresponds to mean ± SD. A star indicates that the mean body
weights differ (p < 0.05, ANOVA followed by Bonferroni’s post hoc test) from the mean body weight of controls (0 mg/kg bw/d) at the same postnatal day.
Table 2
Landmarks of puberty onset in mice treated orally with TPT (0, 1.875, 3.75, 7.5, 15 mg/kg bw/day) from postnatal day (PND) 15–45.
Landmarks TPT (mg/kg bw/day po)
0 1.875 3.75 7.5 15
Female pups, N 23 22 21 26 4
Vaginal opening (VO) day 27 (22–30) 27.5 (23–32) 28 (24–38) 31 (24–44)a 39.5 (31–42)a
Body weight on VO day (g) 17.0 ± 2.4 17.0 ± 2.6 16.7 ± 3.0 17.6 ± 2.6 17.9 ± 0.9
First estrus (FE) day 40 (29–48) 38 (26–53) 41 (31–50) 48.5 (31–53)a,b 51.5 (51–52)a
Body weight on FE day (g) 24.8 ± 3.5 24.4 ± 3.1 26.0 ± 2.0 25.0 ± 2.4 24.8 ± 1.6
Time between VO and FE (days) 12.0 ± 4.2 11.8 ± 6.5 13.0 ± 5.2 11.6 ± 4.4 11.5 ± 2.1
Male pups, N 26 26 24 25 5
Testes  descent (TD) day 21 (19–25) 21 (20–25) 22.5 (20–28)a 23 (21–29)a 29 (27–30)a
Body weight on TD day (g) 11.4 ± 1.1 11.0 ± 1.1 10.8 ± 1.1 10.6 ± 1.1 11.6 ± 1.8
Kruskal–Wallis test and Mann Whitney U test:
a /= control (0 mg/kg bw/d) group.
b /= lowest dose (1.875 mg/kg bw/d) group.
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Table 3
Reproductive organ weights, sperm parameters, and testosterone concentrations in male mice treated orally with TPT (0, 1.875, 3.75, 7.5, 15 mg/kg bw/day)
from  postnatal day (PND) 15–45 and killed at the end of treatment period (PND 46).
Treatment on PND 15–45: Reproductive
parameters on PND 46
TPT (mg/kg bw/day po)
0 1.875 3.75 7.5 15
Male pups, N 14 14 12 13 4
Reproductive organ weights (g)
Testis right 0.12 ± 0.02 0.12 ± 0.01 0.11 ± 0.01 0.12 ± 0.02 0.10 ± 0.01b
left 0.11 ± 0.01 0.12 ± 0.01 0.11 ± 0.01 0.11 ± 0.02 0.10 ± 0.01
Epididymis 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01 0.05 ± 0.01a,b
Seminal vesicle 0.16 ± 0.03 0.16 ± 0.03 0.15 ± 0.02 0.13 ± 0.01a,b 0.08 ± 0.03a,b,c ,d
Spermatid count (× 106/testis), N 8.9 ± 1.7 8.8 ± 2.1 6.9 ± 1.7 6.1 ± 2.1a,b 4.1 ± 1.0a,b
Sperm count (× 106/cauda epididymis), N 16.7 ± 3.9 15.0 ± 3.3 12.4 ± 2.0a 10.3 ± 3.1a,b 3.0 ± 0.9a,b,c ,d
Sperm with abnormal morphology, % 12.70 13.32 10.50 14.50 15.00
Seminiferous tubule diameter, m 231.1 ± 11.70 227.0 ± 8.0 219.4 ± 7.80a 218.6 ± 11.31a 215.0 ± 12.8f
Germinal epithelium heighte, m 68.8 ± 5.9 68.8 ± 6.6 62.2 ± 3.9a,b 64.2 ± 3.9 63.7 ± 1.5
Plasma free testosterone level, pg/mL 16.7 ± 21.8 34.2 ± 32.8 14.4 ± 22.9 18.2 ± 20.7 0.12 ± 0.09
Male  pup body weight on PND 46 (g) 40.8 ± 3.1 41.9 ± 2.3 41.9 ± 3.6 41.6 ± 4.2 35.5 ± 3.2a,b,c ,d
a /= 0 mg/kg bw/d.
b /= 1.875 mg/kg bw/d.
c /= 3.75 mg/kg bw/d.
ous tubu
und in d /= 7.5 mg/kg bw/d.
e Germinal epithelium height was measured in stage VII/VIII seminifer
f Data from three mice were evaluated because no stage VII–VIII was fo
doses of TPT. A decrease of male reproductive organs (testis,
epididymis and seminal vesicle) weight, consistent with a
nearly 10% body weight reduction, was detected in male
mice treated with the highest dose of TPT (15 mg/kg bw/d),
but not among those mice that received 7.5 mg/kg bw/d
or lower doses (Table 3). On PND 46, free testosterone con-
centrations in the plasma of TPT-treated mice did not differ
from the concentrations measured in control group mice
(Table 3).
The morphometrical analysis showed that mice that
received doses of TPT ≥ 3.75 mg/kg bw/d presented a
smaller seminiferous tubule diameter and a reduced ger-
minal epithelium height (Table 3), a ﬁnding suggestive
that treatment with this tri-organotin compound impaired
mouse spermatogenesis.
Histopathology of testicular tissue on PND 46 revealed
sparse alterations of slight to moderate severity such as
increased degree of vacuolation in Sertoli cells (Fig. 2,
panels E and F), presence of immature germ cells (round
spermatids) and cellular debris in the tubule lumen and
signs of degeneration and necrosis of germ cells in the sem-
iniferous tubules of TPT-treated mice (Fig. 2). No alteration
of Leydig cell morphology was noted in the testis of TPT-
treated mice.
3.4. Effect of TPT on male liver and female liver, ovary
and uterus (PND 46)
Post-mortem examination after euthanasia on PND
46 revealed no abnormality and no alteration of repro-
ductive organ (ovary and uteri) weight in female mice
treated with TPT. The relative weights of liver (%; [liver
wt/body wt] × 100), however, were increased (Kruskal
Wallis test and Mann–Whitney U test, p < 0.05) in males
treated with TPT doses ≥7.5 mg/kg bw/d (mg  TPT/kg bw/d;
0: 5.6 ± 0.4, 1.785: 5.7 ± 0.3, 3.75: 5.8 ± 0.4, 7.5: 6.2 ± 0.7,
15.0: 6.6 ± 0.3) and females treated with doses ≥3.75 mg/kgles. ANOVA and Bonferroni’s post hoc test:
the slide from one mouse testis.
bw/d (mg  TPT/kg bw/d; 0: 5.0 ± 0.4, 1.785: 5.4 ± 0.6, 3.75:
5.7 ± 0.6, 7.5: 6.0 ± 0.6, 15.0: 6.3 ± 0.4).
3.5. Effects of TPT on fertility tests and sperm parameters
30 days after treatment discontinuation
The outcome of fertility tests carried out approximately
one month after discontinuation of treatment indicated
that pre/peripubertal exposure to TPT in the dose range
tested did not affect reproductive performance of male
and female mice. As shown in Table 4, ratios of pregnant
females per mated females and of males that copulated
per males that took part in the fertility test did not differ
between controls and TPT-treated mice and, in all dose-
groups percentages of pregnant females were higher than
90% and in most cases 100%. One male that did not copu-
late, and two females that did not become pregnant in the
test were subsequently mated with an untreated female or
male. In this second mating, females were not successfully
impregnated by their male partners, a result that conﬁrmed
that the male and two  females that failed in the ﬁrst test
were in fact infertile. Moreover, data from C-section (per-
formed on GD 16) of females that were impregnated in
the fertility test revealed no difference between control
and TPT-treated groups regarding gravid uteri weight (with
their contents), and numbers of dead and living fetuses,
resorptions and implantations. Post-mortem examination
at the C-section revealed no gross pathology or weight
change of maternal organs and no externally visible abnor-
mality in the recovered fetuses.
TPT-treated male mice euthanized after fertility test
mating period (approx PND 75) exhibited no discernible
difference from controls regarding body weight and repro-
ductive organs (testes, epididymis and seminal vesicle)
weight, spermatid count, sperm count, proportion of sperm
with an abnormal morphology, and plasma free testos-
terone concentrations (Table 5).
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Fig. 2. Testicular histology changes in mice treated with triphenyltin hydroxide (0, 1.875, 3.75, 7.5 or 15 mg/kg bw/d po)  from PND 15–45. Mice were
euthanized at the end of treatment (PND 46). Testes were ﬁxed in Bouin’s solution and Millonig’s buffered formalin as modiﬁed by Carson and stained with
hematoxylin–eosin. Typical histology of a control mouse testis is shown in panel A, while all remaining panels illustrate histological changes found in TPT-
treated animals (B, C–E: 1.875 mg/kg bw/d; G: 3.75 mg/kg bw/d; D, F, H: 7.5 mg/kg bw/d), such as an increased degree of vacuolation of Sertoli cells (panels
E,  F, asterisk *), vacuole apparently associated with germ cell deaths (panel D, asterisk *), acidophilic cells with pyknotic nuclei and hypercondensation of
chromatin (panels G and H, arrows), multinucleated cell aggregates (panels B and C, arrow head). Magniﬁcation: 400×.
Table 4
Outcome of fertility test carried out with male and female mice treated orally with TPT (0, 1.875, 3.75, 7.5, 15 mg/kg bw/day) from postnatal day (PND)
15–45  approximately 20 days after the end of treatment (PND 65).
Treatment on PND 15–45: TPT (mg/kg bw/day po)
0 1.875 3.75 7.5 15
First mating
Copulating males/Mated males (%) 12/12 (100%) 12/12 (100%) 12/12 (100%) 11/12 (91.6%) 2/2 (100%)
Males  impregnating a female/Mated males 12/12a (100%) 10/10 (100%) 9/10 (90%) 11/12 (91.6%) 2/2 (100%)
Pregnant females/Mated females (%) 12/12a (100%) 10/10 (100%) 9/10 (90%) 11/12 (91.6%) 2/2 (100%)
Second  mating
Copulating males/Mated males (%) – – – 0/1 (0%) –
Pregnant females/Mated females (%) – – 0/1 (0%) 0/1 (0%) –
First  plus second mating
Copulating males/Mated males (%) 12/12 (100%) 12/12 (100%) 12/12 (100%) 11/12 (91.6%) 2/2 (100%)
Males  impregnating a female/Mated males 12/12a (100%) 10/10 (100%) 9/10 (90%) 11/12 (91.6%) 2/2 (100%)
Pregnant females/Mated females (%) 12/12a (100%) 10/10 (100%) 9/10 (90%) 11/12 (91.6%) 2/2 (100%)
Implantation sites (N, total)
per litter (mean ± SD)
149
13.6 ± 1.9
140
14.0 ± 2.2
123
13.7 ± 3.2
150
13.6 ± 1.6
27
13.5 ± 3.5
Live  fetuses (N, total)
per litter (mean ± SD)
143
13.0 ± 2.0
135
13.5 ± 2.0
110
12.2 ± 3.4
145
13.2 ± 1.5
23
11.5 ± 0.7
a One pregnant female died during gestation. All other females were pregnant and survived to scheduled C-section (GD16). Statistical analysis revealed
no  difference between control and TPT-treated groups.
Table 5
Reproductive organ weights, sperm parameters, and testosterone concentrations in mice treated orally with TPT (0, 1.875, 3.75, 7.5, 15 mg/kg bw/day)
from  postnatal day (PND) 15–45 and evaluated nearly 30 days after the last administered dose (PND 76).
Treatment on PND 15–45: TPT (mg/kg body wt/day po)
Reproductive parameters on PND 76: 0 1.875 3.75 7.5 15
Male pups, N 12 12 12 12 1
Reproductive organ weights (g)
Testis right 0.13 ± 0.02 0.12 ± 0.02 0.13 ± 0.02 0.13 ± 0.02 0.15
left  0.12 ± 0.01 0.12 ± 0.01 0.13 ± 0.02 0.12 ± 0.02 0.13
Epididymis 0.09 ± 0.01 0.09 ± 0.02 0.09 ± 0.01 0.09 ± 0.02 0.10
Seminal vesicle 0.19 ± 0.03 0.19 ± 0.04 0.20 ± 0.03 0.20 ± 0.03 0.25
Spermatid count (× 106/testis), N 10.0 ± 3.8 8.3 ± 3.7 8.2 ± 3.0 6.4 ± 2.8 10.0
Sperm  count (× 106/cauda epididymis), N 30.2 ± 6.6 30.6 ± 8.1 29.9 ± 6.0 26.9 ± 6.5 20.0
Sperm  with abnormal morphology, % 17.8 19.4 18.6 19.4 19.0
Plasma free testosterone level, pg/mL 27.7 ± 30.2 40.0 ± 34.9 38.6 ± 24.6 38.5 ± 34.7 –
Male  pup body weight on PND 76 (g) 45.4 ± 3.6 44.3 ± 5.4 44.4 ± 3.8 43.7 ± 5.4 45.4
Statistical analysis (0, 1.875, 3.75 and 7.5 mg/kg bw/d) revealed no difference between dose groups.
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4. Discussion
Data from this study showed that treatment of mice
with oral doses of TPT ≥ 7.5 mg/kg/d from PND 15 onwards
resulted in a dose-dependent reduction of pup weight gain
and high mortality rates. All deaths occurred during the
second week of treatment within a few days of weaning
(PND 21–25). No death occurred at the two lowest doses
of TPT tested in this study. A small and transient reduc-
tion of weight gain was noted at 3.75 mg/kg bw/d while
no toxic effect of TPT was detected among mice treated
with 1.875 mg/kg bw/d (Table 1, Fig. 1). Therefore, under
the conditions of this study, the NOAELs for general tox-
icity ﬁndings (weight gain reductions and mortality) were
1.875 mg/kg bw/d (males) and 3.75 mg/kg bw/d (females).
The same NOAEL was set for male reproductive endpoints
(testes descent delay, sperm count and seminiferous tubule
diameter reduction) while 3.75 mg/kg bw/d was the study-
derived NOAEL for female reproductive endpoints.
Delays in the day of vaginal opening completion (VO)
and of day of the ﬁrst estrus (FE) indicated that TPT at doses
≥7.5 mg/kg bw/d retarded puberty onset in females. TPT
at doses ≥3.75 mg/kg bw/d also delayed the day on which
testes descent occurred. Since the body weight on the day
on which these landmark events occurred did not differ
between control and TPT-treated mice, it seems fair to con-
clude that delays in puberty onset in males and females
were associated with a general retardation of growth
and somatic maturation. Notwithstanding this fact, study
results lend support to the interpretation that in rodents
the testis is a target organ for TPT toxicity. Soon after
treatment discontinuation (PND 46) both spermatid and
sperm counts were decreased in a dose-dependent man-
ner in males treated with TPT at doses ≥3.75 mg/kg bw/d.
It is of note that spermatid and sperm count reductions
were consistent with histological examination ﬁndings
that revealed shorter diameters of seminiferous tubules
and a number of signs of degeneration and necrosis of
germ cells (Fig. 2) in the testis of males treated with
TPT at doses ≥3.75 mg/kg bw/d (Table 3). Fertility tests
undertaken nearly 30 days after discontinuation of TPT
administration revealed no decline of fertility in treated
animals (Table 4). Since fertility of males on PND 65–75 was
unaffected by doses of TPT that caused testicular injury and
decreased sperm count on PND 46, either the reduction of
sperm count was insufﬁcient to decrease the reproductive
performance, or a recovery of TPT adverse effects on sperm
parameters was reversed during the 30 days that elapsed
between discontinuation of treatment and the fertility test.
In rats and mice, the sperm count of a normal ejaculate is
far in excess of that number required for 100% of impreg-
nation success. Therefore, if sperm quality and motility are
good, a substantial decline of sperm count is required to
affect the outcome of rodent fertility tests. Since no decline
in sperm count was detected in TPT-treated males on PND
75, it seems fair to conclude that adverse effects of TPT
on mouse spermatogenesis were reversed with treatment
discontinuation.
Two previous studies from our laboratory had found no
effect of TPT on the puberty onset (VO and testes descent)
of the offspring of mice treated (same dose range) duringports 2 (2015) 405–414
pregnancy [4] or pregnancy and lactation [21]. Our previ-
ous negative results are not at odds with the present study
ﬁndings. In this study, pups were directly exposed during
prepubertal and pubertal periods while in the other investi-
gations offspring were exposed via placenta (pregnancy) or
via placenta and maternal milk (pregnancy and lactation).
Kinetic investigations showed that, albeit passing through
the placenta and accumulating in rodent embryos, only
minimal amounts of organotin compounds are transferred
via maternal milk to suckling pups [3,14]). Therefore, our
previous ﬁndings consistently demonstrated that prenatal
exposure to TPT did not affect puberty onset in mice. In this
study pups were exposed directly (by gavage) to TPT and
exposure extended over post-weaning pre- and pubertal
periods.
To the authors’ knowledge, there is no other study on
the effects of similar pre- and pubertal exposures to TPT on
sexual maturation of mice. Reddy et al. [17] reported that
spermatid and sperm counts were reduced in adult (sexu-
ally mature) male mice that received three ip injections of
25 g/kg bw of TPT. They also found decreased activities of
testicular 3- and 17-hydroxysteroid dehydrogenases in
treated mice and suggested that TPT impaired spermato-
genesis due to the inhibition of testosterone production.
As mentioned previously we found a disruption of sem-
iniferous tubules morphology along with unaltered serum
concentrations of free testosterone in mice treated orally
with TPT during pre- and pubertal periods.
In male rats, Grote et al. [6,7] observed that orally
administered TPT (6 mg/kg bw/d) for 30 days (from PND
23 onwards) [6], or TPT (2 mg/kg bw/d) during pregnancy,
lactation (maternal treatment), and post-weaning period
(given directly to pups) until PND 64 [7], decreased testos-
terone serum concentrations. Grote et al. [7], however,
detected no change in serum testosterone concentrations
in mature male rats (PND 64) the treatment of which with
TPT (2 mg/kg/bw/d, administered to mothers) had been
discontinued at weaning. Grote et al. [6] found that TPT
(6 mg/kg/d po, PND 23–53), albeit decreasing testosterone
serum concentrations, did not alter the day of preputial
separation (PS). Nonetheless, a further study by the same
authors [7] revealed that puberty onset (PS) was  delayed
in rats treated with TPT (2 mg/kg bw/d po)  until wean-
ing (PND 21) (no effect on testosterone) and in those that
continued to be treated until PND 64 (decrease of testos-
terone concentrations). Data by Grote et al. [6,7] therefore
suggested that, as far as male rats are concerned, the retar-
dation of puberty onset did not hinge on the depression of
testosterone serum concentrations caused by TPT.
Grote et al. [5,7] also described the effects of TPT on
female rats. A study by Grote et al. [5] found that TPT
administered orally from PND 23 onwards had a biphasic
effect on puberty onset; at a dose as high as 6 mg/kg bw/d
TPT delayed VO while at a lower dose (2 mg/kg bw/d) it
advanced VO. A subsequent study by the same authors
[7], involving pre- and postnatal (until PND 21 or PND 64)
exposure to TPT (2 mg/kg bw/d), found an advancement of
puberty onset (VO) that was more pronounced in the group
the treatment of which was discontinued at weaning (PND
21). Based on the foregoing Grote et al. [7] proposed that
the prenatal period would be a developmental window of
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usceptibility to effects of TPT on puberty onset and that
ales would be more susceptible than females to TPT-
nduced disruption of sexual maturation.
Contrasting to the foregoing results by Grote et al. [5]
e did not observe a treatment-related advancement of
emale mouse puberty onset (VO) at any dose level. The
etardation of VO and FE in mice treated with 7.5 mg/kg
w/d was consistent with Grote et al.’s [5] results show-
ng VO retardation in rats treated with 6 mg/kg bw/d. No
lteration of female puberty onset, however, was  noted
n mice treated with the two lowest doses (1.875 and
.75 mg/kg bw/d), whereas Grote et al. [5] reported that VO
as advanced in rats treated with 2 mg/kg bw/d. For a sim-
lar period of treatment (PND 23 onwards), Grote et al. [6]
ound no effect of TPT on rat preputial separation (6 mg/kg
w/d) while we detected a delay of testes descent and
eduction of sperm count in mice treated with 3.75 and
.5 mg/kg bw/d.
The effects of TBT on sexual maturation were investi-
ated by Si et al. in the offspring of female mice treated
rally (0, 1, 10, 100 g/kg bw/d) during pregnancy (from
D6 on) and throughout lactation until weaning (PND
1). The authors reported results for males [23,24] and
emales [22] in separate publications. Both testes descent
nd acquisition of cliff-drop avoidance reﬂex were slightly,
lbeit signiﬁcantly retarded in males exposed to the high-
st dose (100 g/kg bw/d) [24] while a similar marked
dvancement of VO and FE, with a shortening of VO to FE
ime interval was noted in females treated with all tested
oses [22]. Moreover, Si et al. [22] also demonstrated that
BT-treated females exhibited body weights lower than
hose of untreated controls on the day of VO and FE and
hat in addition to an early puberty onset TBT also dis-
upted normal cycling in mature female mice. Nonetheless,
he effect of 1 g/kg bw/d was almost identical to that of a
00-fold higher dose (100 g/kg bw/d). The absence of any
hange of the magnitude of the toxic response over such a
road range of doses tested by Si et al. [22] is an intriguing
nding.
At any rate, a distinction should be made between “pro-
ramming effects” of exposure to organotin compounds
uring prenatal and or neonatal periods affecting further
exual maturation, and effects on puberty onset somatic
andmarks arising from exposures that take place later
i.e., pre/pubertal exposures) when the process is going
n. Effects of TBT on female mouse puberty onset estrous
yclicity and reported by Si et al. [22] possibly arise from a
pigenetic “programming” effect elicited during in utero
nd neonatal periods and appear to be persistent. The
ffects reported in the present study, on the other hand,
ere transient effects of doses of TPT that were also asso-
iated to non-reproductive toxicity.
Recently, Mitra et al. [13] reported that, in in vitro
erm-cell Sertoli cell co-cultures, TBT (300–1000 nM
oncentration range) induced stress proteins and mito-
hondrial depolarization leading to caspase-3-activation
nd apoptotic (at lower concentrations) and necrotic (at
igher concentrations) cell deaths. They also noted that
ertoli cells were more susceptible than germ cells. More-
ver, the authors demonstrated that, in rats, an oral dose as
igh as 50 mg/kg bw disrupted the blood-testicular-barrier.ports 2 (2015) 405–414 413
Mitra et al. [13] suggested that damage to Sertoli cells
plays a pivotal role in tri-organotin compounds-mediated
testicular toxicity. The histopathological changes in the
seminiferous tubules of TPT treated mice (vacuolation in
Sertoli cells and degeneration and necrosis of germ cells)
seem to be consistent with Mitra et al.’s hypothesis.
In conclusion, repeated exposure of mice to TPT by
the oral route during pre- and pubertal periods caused
in addition to non-reproductive toxic effects, a high mor-
tality and a delay of puberty onset in females (vaginal
opening and ﬁrst estrus) and in males (testes descent), a
decline of spermatid and sperm counts, and slight to mod-
erate damage to testicular Sertoli and germ cells. There
was an overlap between doses that cause general toxicity
(deaths and weight gain deﬁcits) and reproductive toxicity
in males (NOAEL 1.875 mg/kg bw/d) and females (NOAEL
3.75 mg/kgbw/d). TPT-induced decline of spermatid/sperm
counts were reversed after treatment discontinuation. No
effect of pre-pubertal/pubertal treatment with TPT was
detected on the outcome of fertility tests performed with
mature mice. It is of note that NOAELs for reproductive
toxicity determined in this rodent study are orders of
magnitude much higher than estimated human exposures.
Notwithstanding the fact that data on human exposure
to organotins (OTCs) are scanty, a Finnish study esti-
mated that the average daily intake of OTCs through ﬁsh
consumption (a main dietary source of organotins) was
3.2 ng/kg bw/d, which corresponds to 1.3% from tolerable
daily intake of 250 ng/kg bw/d set by the European Food
Safety Authority [1]. A study by Rantakokko et al. [16]
determined blood concentrations of TPTs in Finnish ﬁsh-
ermen and their relatives and found that in only 27 out
of 300 samples analyzed TPT concentrations were higher
than limit of quantiﬁcation of the method (0.04 ng/mL). The
maximum TPT blood concentration found by Rantakokko
et al. [16] was 0.56 ng/mL.
Transparency document
The Transparency document associated with this article
can be found in the online version.
Acknowledgements
The research project was funded by the Brazilian
National Research Council (CNPq), FAPERJ, and FIOCRUZ
(PAPES-III). This study is part of MSCM doctoral thesis
(INCQS-FIOCRUZ). FJRP, IFD and WGK  are recipients of
research fellowships from CNPq.
References
[1] R. Airaksinen, P. Rantakokko, A.W. Turunen, T. Vartiainen, P.J.
Vuorinen, A. Lappalainen, A. Vihervuori, J. Mannio, A. Hallikainen,
Organotin intake through ﬁsh consumption in Finland, Environ. Res.
110 (6) (2010) 544–547.
[2] R.P. Amann, Detection of alterations in testicular and epididymal
function in laboratory animals, Environ. Health Perspect. 70 (1986)
149–158.
[3] G.M. Cooke, D.S. Forsyth, G.S. Bondy, R. Tachon, B. Tague, L. Coady,
Organotin speciation and tissue distribution in rat dams, fetuses,
and neonates following oral administration of tributyltin chloride,
J. Toxicol. Environ. Health A 71 (6) (2008) 384–395.
ology Re
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[414 M.S.C. Mello et al. / Toxic
[4] I.F. Delgado, V.G. Viana, M.  Sarpa, F.J. Paumgartten, Postnatal devel-
opment and resistance to Plasmodium yoelii infection of mice
prenatally exposed to triphenyltin hydroxide, Environ. Toxicol. 24
(6)  (2009) 629–635.
[5] K. Grote, A.J. Andrade, S.W. Grande, S.N. Kuriyama, C.E. Talsness, K.E.
Appel, I. Chahoud, Effects of peripubertal exposure to triphenyltin on
female sexual development of the rat, Toxicology 222 (1–2) (2006)
17–24.
[6] K. Grote, B. Stahlschmidt, C.E. Talsness, C. Gericke, K.E. Appel, I.
Chahoud, Effects of organotin compounds on pubertal male rats,
Toxicology 202 (3) (2004) 145–158.
[7] K. Grote, C. Hobler, A.J. Andrade, S.W. Grande, C. Gericke, C.E. Tal-
sness, K.E. Appel, I. Chahoud, Sex differences in effects on sexual
development in rat offspring after pre- and postnatal exposure to
triphenyltin chloride, Toxicology 260 (1–3) (2009) 53–59.
[8] Y. Hiromori, J. Nishikawa, I. Yoshida, H. Nagase, T. Nakan-
ishi, Structure-dependent activation of peroxisome proliferator-
activated receptor (PPAR) gamma  by organotin compounds? Chem.
Biol. Interact. 180 (2) (2009) 238–244.
[9] T. Horiguchi, Masculinization of female gastropod mollusks induced
by  organotin compounds, focusing on mechanism of actions of trib-
utyltin and triphenyltin for development of imposex, Environ. Sci. 13
(2) (2006) 77–87.
10] T. Kanayama, N. Kobayashi, S. Mamiya, T. Nakanishi, J. Nishikawa,
Organotin compounds promote adipocyte differentiation as
agonists of the peroxisome proliferator-activated receptor
gamma/retinoid X receptor pathway? Mol. Pharmacol. 67 (3) (2005)
766–774.
11] P. Lang-Podratz, V.S. Delgado Filho, P.F. Lopes, G. Cavati Sena,
S.T. Matsumoto, V.Y. Samoto, C.M. Takiya, E. de Castro Miguel,
I.V. Silva, J.B. Graceli, Tributyltin impairs the reproductive cycle
in  female rats, J. Toxicol. Environ. Health A 75 (16–17) (2012)
1035–1046.
12] A. Le Maire, M.  Grimaldi, D. Roecklin, S. Dagnino, V. Vivat-Hannah,
P.  Balaguer, W.  Bourguet, Activation of RXR-PPAR heterodimers by
organotin environmental endocrine disruptors, EMBO Rep. 10 (4)
(2009) 367–373.
13] S. Mitra, A. Srivastava, S. Khandelwal, Tributyltin chloride induced
testicular toxicity by JNK and p38 activation, redox imbalance and
cell death in sertoli-germ cell co-culture, Toxicology 314 (1) (2013)
39–50.
14] V.C. Moser, J.K. McGee, K.D. Ehman, Concentration and persistence
of  tin in rat brain and blood following dibutyltin exposure during
development, J. Toxicol. Environ. Health A 72 (1) (2009) 47–52.
[ports 2 (2015) 405–414
15] T. Nakanishi, Endocrine disruption induced by organotin com-
pounds; organotins function as a powerful agonist for nuclear
receptors rather than an aromatase inhibitor? J. Toxicol. Sci. 33 (3)
(2008) 269–276.
16] P. Rantakokko, A. Turunen, P.K. Verkasalo, H. Kiviranta, S. Männistö,
T.  Vartiainen, Blood levels of organotin compounds and their relation
to  ﬁsh consumption in Finland? Sci. Total Environ. 399 (1–3) (2008)
90–95.
17] P.S. Reddy, T. Pushpalatha, P.S. Reddy, Reduction of spermatogenesis
and steroidogenesis in mice after fentin and fenbutatin administra-
tion, Toxicol. Lett. 166 (1) (2006) 53–59.
18] G.W. Robb, R.P. Amann, G.J. Killian, Daily sperm production and epi-
didymal sperm reserves of pubertal and adult rats, J. Reprod. Fertil.
54  (1) (1978) 103–107.
19] E. Salewski, Faerbemethoden zum Makroskopischen Nachweis von
Implantationsstellen am Uterus der Ratte, Naunyn-Schmiedebergs
Archiv fuer Experimentelle Pathologie und Pharmakologie 247
(1964) 367.
20] M.  Sarpa, R.R. De-Carvalho, I.F. Delgado, F.J. Paumgartten, Develop-
mental toxicity of triphenyltin hydroxide in mice, Regul. Toxicol.
Pharmacol. 49 (1) (2007) 43–52.
21] M.  Sarpa, C.M. Tavares Lopes, I.F. Delgado, F.J. Paumgartten, Postnatal
development and fertility of offspring from mice exposed to triph-
enyltin (fentin) hydroxide during pregnancy and lactation, J. Toxicol.
Environ. Health A 73 (13–14) (2010) 965–971.
22] J. Si, X. Han, F. Zhang, Q. Xin, L. An, G. Li, C. Li, Perinatal exposure to low
doses of tributyltin chloride advances puberty and affects patterns
of  estrous cyclicity in female mice, Environ. Toxicol. 27 (11) (2012)
662–670.
23] J. Si, P. Li, Q. Xin, X. Li, L. An, J. Li, Perinatal exposure to low doses
of tributyltin chloride reduces sperm count and quality in mice,
Environ. Toxicol. (2013), http://dx.doi.org/10.1002/tox.21892 [Epub
ahead of print].
24] J. Si, J. Li, F. Zhang, G. Li, Q. Xin, B. Dai, Effects of perinatal exposure to
low doses of tributyltin chloride on pregnancy outcome and postna-
tal  development in mouse offspring, Environ. Toxicol. 27 (10) (2012)
605–612.
25] C.P. Titley-O’Neal, K.R. Munkittrick, B.A. Macdonald, The effects of
organotin on female gastropods, J. Environ. Monit. 13 (9) (2011)
2360–2388.
26] B. Watermann, K. Grote, K. Gnass, H. Kolodzey, A. Thomsen, K.E.
Appel, D. Candia-Carnevali, U. Schulte-Oehlmann, Histological alter-
ations in ovaries of pubertal female rats induced by triphenyltin?
Exp. Toxicol. Pathol. 60 (4–5) (2008) 313–321.
